Duloxetine Hcl Capsule, Delayed Release
Product Images NDC 80425-0014

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine Hcl (NDC 80425-0014). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Fig 1 (Fig 1)

Fig 1 (Fig 1)
A Kaplan-Meier survival curve comparing the proportion of patients with relapse over time (days) following randomization between Duloxetine and placebo groups. The graph plots the relapse proportion on the y-axis against time in days on the x-axis, showing separate lines for Duloxetine and placebo treatment groups.*
FDA Label Image

Fig 10 (Fig 10)

Fig 10 (Fig 10)
A line chart comparing the percentage of patients improved by placebo versus duloxetine 60/120 mg once daily. The x-axis represents percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved. Duloxetine consistently shows higher patient improvement across all levels of pain reduction compared to placebo.*
FDA Label Image

Fig 2 (Fig 2)

Fig 2 (Fig 2)
A line chart showing the proportion of patients with relapse over time in days from randomization. It compares two treatments: placebo (dashed line) and duloxetine (solid line), illustrating relapse rates up to approximately 250 days.*
FDA Label Image

Fig 3 (Fig 3)

Fig 3 (Fig 3)
A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for four groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and Placebo. The graph illustrates trends in patient improvement across these treatment groups.*
FDA Label Image

Fig 4 (Fig 4)

Fig 4 (Fig 4)
A line graph comparing the percentage of patients improved by pain over time for Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), and placebo. The x-axis shows percent improvement in pain from baseline (0 to 100%), and the y-axis shows the percentage of patients improved. The graph illustrates trends in patient improvement for the three groups.*
FDA Label Image

Fig 5 (Fig 5)

Fig 5 (Fig 5)
A line graph depicting the percentage of patients improved versus the percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The y-axis shows percentage of patients improved from 0 to 100%, while the x-axis shows percent improvement in pain from baseline ranging from greater than 0 to 100%.*
FDA Label Image

Fig 6 (Fig 6)

Fig 6 (Fig 6)
A line graph comparing the percent of patients improved by percent improvement in pain from baseline for Duloxetine at 120 mg, 60 mg, and 20 mg once daily doses versus placebo. The graph shows a higher percentage of patients improved with Duloxetine treatments compared to placebo across different improvement levels.*
FDA Label Image

Fig 8 (Fig 8)

Fig 8 (Fig 8)
A line graph comparing the percentage of patients improved with placebo and Duloxetine 60/120 mg once daily. The x-axis shows percent improvement in pain from baseline (BOCF) from 0 to 100, and the y-axis shows the percentage of patients improved from 0 to 100. Two lines with markers represent patient improvement under each treatment over the range of pain improvement percentages.*
FDA Label Image

Fig 9 (Fig 9)

Fig 9 (Fig 9)
A line graph comparing the percentage of patients improved at various levels of percent improvement in pain from baseline between placebo and Duloxetine 60 mg once daily. The x-axis represents percent improvement in pain from baseline, while the y-axis shows the percentage of patients improved. Two lines depict outcomes for placebo (dotted) and Duloxetine (solid).*
FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure of Duloxetine HCL, showing its molecular framework including aromatic rings, a sulfur-containing thiophene ring, and the side chain with an amine hydrochloride group.*
FDA Label Image

Label 1 (Label 1)

Label 1 (Label 1)
Duloxetine HCL DR 30 mg delayed release capsules label from Advanced Rx of Tennessee, LLC. The label includes dosage strength 30 mg, oral route, and a quantity of 30 capsules. It shows storage instructions at 20-25°C (68-77°F), a barcode, lot number 30DUL301221, and expiration date 1/1/2022. The label also includes a comparison to Cymbalta and mentions Rising Pharm in a barcode section.*
FDA Label Image

Label 2 (Label 2)

Label 2 (Label 2)
Label for Duloxetine HCL 30 mg delayed-release capsules from Advanced Rx of Tennessee, LLC. The label includes storage instructions (20°-25°C), a comparison to Cymbalta with corresponding NDC numbers, lot number 60DUL301221, and expiration date 1/1/2022. The label also displays a barcode and a caution about prescription transfer limitations.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.